You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting Myosin to Treat Polycystic Kidney Disease

    SBC: PLUREXA LLC            Topic: 400

    PROJECT SUMMARY The goal of this proposal is to advance a new therapeutic approach targeting myosin for polycystic kidney disease (PKD). PKD is a major life-threatening Mendelian disorder that affects 12,000,000 individuals, representing a market opportunity of ~$1 billion. In PKD, tiny tubules in the kidneys, liver, and other organs gradually expand into fluid-filled cysts, leading to organ failu ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis

    SBC: KULEANA TECHNOLOGY, INC.            Topic: 400

    PROJECT SUMMARY/ ABSTRACT Currently in the US there are over 400,000 kidney patients on dialysis. The primary therapy mode is hemodialysis and is performed in a hospital or private clinic. Current dialysis therapy requires a large device that must be continuously connected to a reverse osmosis (RO) system. A single treatment will require over 150L of AAMI dialysate making portable device unattaina ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel diagnostic biomarker reference standards for newborn screening of Mucopolysaccharidoses type I and II.

    SBC: GELBCHEM, LLC            Topic: NICHD

    Project Summary The goal of this project is to design and prepare diagnostic biomarker reference standards for the endogenous glycosaminoglycan (GAG) Mucopolysaccharidosis type I (MPS-I) and type II (MPS- II) biomarkers. MPS-I and MPS-II are lysosomal storage disorders (LSDs) which are listed on the Recommended Uniform Screening Panel (RUSP) in the United States and are included in global Newborn ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. iKinnect Mobile Technology to Reduce Teen Substance Misuse and Health Disparities

    SBC: EVIDENCE-BASED PRACTICE INSTITUTE, INC.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACTAdolescent substance abuse (SA) has been called America’s #1 public health problem, affecting as many as 16% of all youth under age 18 and often resulting in serious consequences such as criminal involvement, health problems, and suicide. Given that adolescent SA is associated with high rates of comorbidity with mental health (MH) problems and increased suicide risk, inte ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Multiplexed biosensor for personal wildfire exposure assessment

    SBC: DL ADV-TECH, LLC            Topic: R

    Summary/Abstract: Wildfire are becoming more frequently and severe due to climate change, resulting in growing exposures of major population to high level of benzene and polycyclic aromatic hydrocarbons from biomass-burning emissions. Wildfire exposure pose a serious threat to the health and the well-being of humans. Currently, assessment of personal exposure to wildfire is dependent on taking env ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins

    SBC: TALUS BIOSCIENCE INC            Topic: 400

    SUMMARY To evaluate how a drug candidate affects cells, researchers often study how the abundance or behavior of a specific set of proteins is changed by treatment with each compound. However, it is not currently possible to test the effect of every possible drug compound (rt500,000) on every human protein (~20,000) in hundreds of different types of cells. Even the most advanced protein analysis s ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors

    SBC: TALUS BIOSCIENCE INC            Topic: 100

    RESEARCH SUMMARY The human genome encodes more than 1,600 transcription factors (TFs), along with additional cofactors, chromatin regulators, and structural proteins that collectively execute the regulatory instructions encoded within the nuclear DNA. Dysfunctions of these proteins are known to drive multiple diseases such as cancer, inflammation-related, and neurological conditions. In cancer, th ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines

    SBC: Vitakey Inc.            Topic: 300

    Project Summary/Abstract Enteral feeding (EF) is an essential medical procedure used to supply nutrients directly to the gastrointestinal (GI) tract of patients who are unable to eat independently. EF formula is often purchased as a ready-to-use liquid that contains carbohydrates, protein, fats, and micronutrients to ensure adequate nutritional benefit for the patient. The addition of therapeutic ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government